The Indian rhesus macaque develops a disease that closely mimics human acquired immunodeficiency syndrome (AIDS) when infected by simian Immunodeficiency virus (SIV) or chimeric simian-human immunodeficiency viruses (SHIV), and represents the best animal model for HIV Infection. Preclinical vaccine development is heavily dependent on the SIV and SHIV rhesus macaque models. The value and utility of the model are markedly enhanced by improving the level of microbial and genetic characterization. Macaques free of ubiquitous viruses that are homologues of human viruses responsible for opportunistic infections are essential for a growing number of AIDS-related opportunistic infection models and for viral vaccine vector development based on these agents. The utility of macaque models for immunological research has been hindered by the unprecedented complexity of their major histocompatibility complexes. Comprehensive MHC genotyping has the potential to revolutionize the use of macaques in infectious disease research and to guide functional immunology studies. MHC-restricted cellular immune responses are key in protective immunity and resistance to infectious diseases. The comprehensive objective of this application is to increase the capacity of the ONPRC AIDS Research Expanded SPF Breeding Colony to provide genetically characterized lndian-origln rhesus macaques free of a broad number of enzootic and zoonotic agents to enhance the usefulness of the resource for cutting edge opportunistic agent and vaccine research.

Public Health Relevance

Expanded breeding of specific pathogen free Indian-origin rhesus macaques and extended MHC genotyping have repeatedly been identified as priorities for mitigating chronic shortages of animals for research and to improve their usefulness to better understand MHC-restricted cellular immunity. The ONPRC Expanded SPF rhesus macaque breeding colony is directly responsive to these national priorities.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, National Institutes of Health (OD)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24OD010850-12
Application #
8515544
Study Section
Special Emphasis Panel (ZRR1-CM-1 (01))
Program Officer
Contreras, Miguel A
Project Start
2002-09-30
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
12
Fiscal Year
2013
Total Cost
$714,389
Indirect Cost
$306,167
Name
Oregon Health and Science University
Department
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Hansen, Scott G; Wu, Helen L; Burwitz, Benjamin J et al. (2016) Broadly targeted CD8⁺ T cell responses restricted by major histocompatibility complex E. Science 351:714-20
Estep, Ryan D; Rawlings, Stephanie D; Li, Helen et al. (2014) The rhesus rhadinovirus CD200 homologue affects immune responses and viral loads during in vivo infection. J Virol 88:10635-54
Malouli, Daniel; Hansen, Scott G; Nakayasu, Ernesto S et al. (2014) Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. J Clin Invest 124:1928-44
Hansen, Scott G; Piatak Jr, Michael; Ventura, Abigail B et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 502:100-4
Hansen, Scott G; Sacha, Jonah B; Hughes, Colette M et al. (2013) Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340:1237874
Fukazawa, Yoshinori; Park, Haesun; Cameron, Mark J et al. (2012) Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 18:1673-81
Hansen, Scott G; Ford, Julia C; Lewis, Matthew S et al. (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-7